current
avail
diagnost
assay
leptospirosi
differenti
vaccin
infect
serum
antibodi
sever
leptospir
protein
upregul
infect
describ
util
diagnost
marker
still
unclear
studi
undertook
lipidom
approach
determin
differ
serum
lipid
profil
hors
natur
infect
pathogen
leptospira
spp
hors
vaccin
commerci
avail
bacterin
util
highresolut
mass
spectrometri
serum
lipidom
analyt
platform
demonstr
cyclic
phosphatid
acid
diacylglycerol
hydroperoxid
oxid
product
cholin
plasmalogen
elev
serum
natur
infect
well
vaccin
hors
lipid
interest
triacylglycerol
elev
serum
infect
hors
sphingomyelin
increas
serum
vaccin
hors
first
report
look
equin
serum
lipidom
leptospir
infect
vaccin
leptospirosi
worldwid
zoonot
diseas
affect
hors
mani
mammalian
speci
includ
man
leptospira
interrogan
serovar
pomona
commonli
associ
clinic
leptospirosi
hors
unit
state
diseas
hors
mainli
character
spontan
abort
recurr
uveiti
leptospir
abort
occur
late
gestat
typic
without
prior
clinic
sign
infect
mare
shed
leptospir
urin
week
potenti
sourc
infect
anim
recurr
uveiti
import
sequela
leptospir
infect
major
caus
blind
hors
leptospir
serosurveil
conduct
report
preval
among
hors
popul
state
unit
state
canadian
provinc
microscop
agglutin
test
mat
gold
standard
serodiagnosi
leptospirosi
mat
perform
mix
serial
dilut
patient
serum
batteri
live
leptospira
serovar
presenc
leptospir
antibodi
serum
detect
darkfield
microscop
examin
agglutin
among
sever
obviou
limit
mat
test
inabl
distinguish
leptospir
antibodi
gener
result
natur
infect
vaccin
vaccin
hors
antibodi
leptospir
bacterin
give
posit
agglutin
reaction
mat
test
overcom
technic
limit
mat
distinguish
infect
vaccin
hors
would
improv
diagnosi
equin
leptospirosi
recent
advanc
leptospir
research
result
identif
number
immunogen
leptospir
protein
either
exclus
express
significantli
upregul
infect
hors
use
differenti
infect
vaccin
hors
still
investig
result
current
diagnost
test
differenti
two
immun
respons
alter
lipid
metabol
due
pathogeninduc
immun
activ
previous
report
studi
ask
differ
host
respons
live
multipli
leptospira
versu
kill
leptospir
present
vaccin
reflect
serum
lipidom
two
group
hors
end
use
nontarget
lipidom
approach
compar
serum
lipidom
hors
leptospir
infect
hors
vaccin
commerci
avail
bacterin
fifteen
serum
sampl
three
group
hors
use
studi
unvaccin
natur
infect
microscop
agglutin
test
mat
posit
hors
hors
vaccin
lepto
eq
innov
zoeti
inc
kalamazoo
mi
unvaccin
unexpos
matneg
hors
tabl
initi
screen
perform
mat
follow
oie
protocol
http
natur
infect
hors
never
vaccin
mat
titer
tabl
hors
vaccin
group
histori
prior
exposur
leptospira
spp
rule
prior
exposur
possibl
control
group
hors
never
vaccin
known
histori
prior
exposur
vaccin
six
fifteen
sampl
infect
group
sent
ukvdl
mat
titer
remain
nine
sampl
infect
group
collect
two
differ
farm
virginia
kentucki
five
millilit
blood
obtain
jugular
vein
hors
use
vacutain
needl
sleev
ml
dri
blood
collect
tube
red
top
clot
blood
sampl
centrifug
x
g
minut
serum
separ
store
frozen
requir
ship
dri
ice
none
sampl
thaw
time
lipidom
analys
done
sampl
use
studi
leftov
aliquot
either
clinic
diagnost
sampl
univers
kentucki
veterinari
diagnost
laboratori
blood
sampl
collect
phlebotomi
teach
lab
phlebotomi
lab
protocol
approv
lincoln
memori
univers
institut
anim
care
use
committe
lipid
extract
serum
vortex
ml
methanol
contain
stabl
isotop
intern
standard
next
ml
water
ml
methyltertbutyl
ether
ad
tube
vigor
shaken
room
temperatur
min
tube
next
centrifug
xg
min
room
temperatur
ml
upper
organ
extract
dri
centrifug
vacuum
evapor
dissolv
isopropanol
methanol
chloroform
contain
mm
ammonium
acet
constant
infus
lipidom
perform
util
highresolut
amu
data
acquisit
submillimass
accuraci
orbitrap
mass
spectromet
thermo
q
exact
success
switch
polar
mode
neg
ion
esi
anion
ethanolamin
plasmalogen
plse
phosphatidylethanolamin
ptde
lysophosphoethanolamin
lpe
phosphatidylglycerol
pg
phosphatid
acid
pa
lysophosphatid
acid
lpa
cyclic
phosphatid
acid
cpa
phosphatidylinositol
pi
ceramid
phosphatidylserin
ps
quantit
lipid
ident
valid
msm
posit
ion
esi
cation
cholin
plasmalogen
plsc
hydroperoxi
plsc
phosphatidylcholin
ptdc
lysophosphocholin
lpc
sphingomyelin
sm
monoacylglycerol
mg
acylcarnitin
acar
ammonium
adduct
diacylglycerol
dg
triacylglycerol
tg
cholesterol
ester
ce
quantit
lipid
ident
valid
msm
case
hydroperoxi
plsc
structur
ident
valid
loss
h
ms
gener
major
fragment
cholin
phosphat
cation
anion
bromocriptin
use
monitor
potenti
mass
axi
drift
inject
transfer
line
wash
success
wash
methanol
hexaneethyl
acetatechloroform
minim
potenti
ghost
effect
r
valu
ratio
endogen
lipid
peak
area
peak
area
appropri
intern
standard
per
serum
calcul
data
present
mean
sem
data
analyz
anova
follow
dunnet
test
compar
vaccin
infect
group
control
individu
data
valu
avail
supplementari
inform
tabl
result
cpa
fig
elev
serum
vaccin
infect
equin
group
tandem
mass
spectrometri
valid
structur
cpa
anion
glycerophosph
h
monitor
ppm
mass
error
respect
tabl
cyclic
phosphatid
acid
also
elev
serum
vaccin
infect
group
includ
cpa
cpa
cpa
fig
structur
valid
ms
product
anion
glycerophosph
h
monitor
cpa
respect
fatti
acid
constitu
monitor
tabl
data
clearli
demonstr
immun
respons
initi
leptospirosi
vaccin
result
gener
cpa
may
import
indic
immun
activ
particular
interest
hors
vaccin
demonstr
mat
titer
tabl
contrast
cpa
chang
similar
vaccin
hors
detect
indic
lipid
sensit
indic
immun
activ
cyclic
phosphatid
acid
gener
phospholipas
ddepend
transphosphatidyl
lysophosphatidylcholin
gener
phospholipas
hydrolysi
phosphatidylcholin
fig
parallel
augment
cpa
monitor
increas
serum
level
associ
lysophosphatidylcholin
lpc
precursor
fig
albeit
increas
lpc
level
greater
vaccin
compar
infect
hors
p
diacylglycerol
dag
also
elev
serum
vaccin
infect
hors
includ
dag
dag
dag
dag
dag
fig
dag
dag
dag
particular
interest
hors
vaccin
demonstr
mat
titer
tabl
contrast
dag
chang
similar
vaccin
hors
detect
indic
lipid
sensit
indic
immun
activ
contrast
triacylglycerol
increas
serum
infect
hors
includ
tag
tag
tag
tag
tag
tag
tag
fig
tag
tag
tag
tag
tag
evalu
sphingolipid
note
sphingomyelin
select
elev
serum
vaccin
hors
includ
sm
sm
sm
sm
sm
fig
sm
sm
fig
sm
contrast
sm
chang
similar
vaccin
hors
detect
indic
lipid
sensit
indic
immun
activ
infect
gener
result
induct
serin
palmitoyltransferas
therebi
augment
sphingomyelin
synthesi
univers
note
hydroperoxi
oxid
product
number
cholin
plasmalogen
possess
unsatur
fatti
acid
substitu
detect
infect
vaccin
hors
greater
vaccin
group
fig
ident
oxid
product
valid
via
tandem
mass
spectrometri
use
approach
monitor
loss
h
h
tabl
gener
cholin
phosphat
ppm
mass
error
hallmark
featur
class
oxid
lipid
ever
increas
knowledg
base
regard
biochemistri
immun
respons
infect
inflammatori
diseas
shift
respons
gener
result
upregul
proinflammatori
cytokin
bacteri
infect
viral
infect
parasit
invas
addit
local
immun
respons
lung
brain
intestin
inflammatori
bowel
diseas
crohn
diseas
ulcer
coliti
elicit
alter
cytokin
respons
proinflammatori
cytokin
act
induc
therebi
act
deplet
tryptophan
gener
kynurenin
result
activ
pathway
kyneureninetryptophan
ratio
often
use
surrog
biomark
immun
activ
lipid
metabol
also
alter
acut
phase
reactant
respons
exampl
elev
level
circul
triglycerid
observ
experiment
cytokin
lipopolysaccharid
inject
result
augment
hepat
lipogenesi
elev
triglycerid
also
consist
report
bacteri
parasit
infect
alter
sphingomyelin
metabol
also
report
increas
pneumonia
patient
decreas
hiv
patient
evalu
alter
serum
lipidom
immun
activ
took
advantag
opportun
compar
serum
lipidom
hors
activ
leptospirosi
infect
hors
vaccin
commerci
bacterin
result
show
serum
level
cyclic
phosphatid
acid
cpa
diacylglycerol
hydroperoxid
oxid
product
cholin
plasmalogen
elev
vaccin
natur
infect
hors
perhap
importantli
observ
triacylglycerol
elev
serum
infect
hors
sphingomyelin
increas
serum
vaccin
hors
previou
ongo
studi
lab
demonstr
increas
level
cpa
airway
surfact
hors
asthma
phospholipas
pld
augment
earli
phase
infect
suggest
cpa
biomark
may
simpl
biochem
readout
induct
enzym
immun
activ
see
fig
particular
note
data
first
demonstr
vaccin
activ
enzym
system
data
suggest
cpa
may
use
global
biomark
immun
activ
variou
infect
hors
possibl
anim
speci
consid
breadth
bioactiv
class
lipid
contribut
immun
respons
may
divers
particularli
sinc
modul
nuclear
function
regard
pharmacolog
studi
shown
cpa
analog
potent
revers
experiment
osteoarthr
block
immuneinduc
demyelin
inhibit
growth
cancer
cell
plasmalogen
essenti
membran
lipid
particularli
lipid
raft
alter
structur
glycerophospholipid
induc
lipid
oxid
may
play
role
host
immun
respons
particularli
develop
immun
evidenc
dramat
increas
circul
hydroperoxi
cholin
plasmalogen
leptospiravaccin
anim
role
singlet
oxygenoxid
free
radic
andor
oxygenas
product
lipid
vaccin
remain
defin
studi
demonstr
triacylglycerol
tag
elev
serum
natur
infect
hors
previou
report
also
consist
demonstr
elev
serum
level
tag
experiment
clinic
unresolv
immun
activ
includ
human
leptospirosi
mechan
involv
immunedepend
hypertriglyceridemia
thought
involv
cytokin
activ
triglycerid
synthesi
liver
contrast
dag
elev
infect
vaccin
cohort
suggest
synthesi
metabol
neutral
lipid
alter
resolv
unresolv
immun
activ
first
report
chang
dag
level
immun
activ
regard
report
increas
express
pld
earli
phase
infect
suggest
immuneactiv
mechan
may
involv
gener
increas
level
dag
glycerophospholipid
sinc
pld
metabol
glycerophospholipid
phosphatid
acid
direct
precursor
dag
studi
sphingomyelin
increas
serum
vaccin
hors
sphingomyelin
level
previous
shown
elev
patient
pneumonia
melioidosi
unalt
sever
bacterem
condit
decreas
aid
patient
data
indic
immun
respons
induc
vaccin
dramat
effect
leptospir
infect
sphingomyelin
synthesi
hors
role
lipid
immun
respons
remain
clearli
defin
summari
result
provid
import
inform
differ
serum
lipidom
natur
infect
leptospiravaccin
hors
sinc
studi
util
diagnost
clinic
sampl
control
timematch
studi
requir
ascertain
use
candid
lipid
differenti
vaccin
infect
respons
leptospira
spp
support
inform
tabl
xlsx
